| Use of sirolimus to facilitate steroid withdrawal from a cyclosporine regimen. | |
| | |
MedLine Citation:
|
PMID: 17112844 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Chronic steroid therapy has been associated with many comorbidities of transplant immunosuppression. Because sirolimus blocks one of the sites affected by steroids, we sought to examine whether substituting this drug mitigated these toxicities. METHODS: We used intent-to-treat methodology to compare the clinical outcomes and laboratory results between 30 renal transplant recipients converted from steroids to sirolimus with a cohort of demographically matched subjects who were transplanted concurrently with the study group and maintained on steroids. All patients received ongoing cyclosporine-based immunosuppression. To compensate for pharmacokinetic interactions with sirolimus, the cyclosporine exposure was markedly reduced in the study group. Statistical comparisons utilized analysis of variance, chi-square tests, and log rank evaluation of Kaplan-Meier curves. RESULTS: Conversion from prednisone to sirolimus was accomplished without difficulty in 27 of 30 patients. Treatment failures among the converted patients were due to chronic allograft nephropathy (n = 1), recurrence of original disease (n = 1), or chronic rejection (n = 2). By intent-to-treat analysis, the outcomes were similar in the study versus concurrent control groups. Laboratory values showed triglyceridemia as an adverse reaction to sirolimus, and reduced leukocytes, to steroid withdrawal. The observed clinical benefits solely reflected the markedly reduced cyclosporine exposure. Based on responses to a questionnaire administered prior to versus 12 and 24 months after steroid withdrawal, several domains revealed improvements in subjective complaints. CONCLUSION: Conversion from prednisone to sirolimus in combination with cyclosporine was easily accomplished in most renal transplant recipients. Although a 2-year follow-up failed to reveal objective benefits of the maneuver (other than those consequent to reduced cyclosporine exposure), most patients reported a subjectively improved health status. |
| | |
Authors:
|
B D Kahan; J Podbielski; L Schoenberg |
Related Documents
:
|
12707574 - Transplant immunosuppressant agents and their role in autoimmune rheumatic diseases. 19744094 - Two-year follow-up of a prospective study of circulating regulatory t cells in renal tr... 16413244 - Intestinal mdr1/abcb1 level at surgery as a risk factor of acute cellular rejection in ... 15561004 - Recovery of chronic renal impairment with sirolimus after lung transplantation. 16180554 - Joint working with hospice teams: a renal collaborative approach. 22493334 - Multiplex pcr for rapid and improved diagnosis of bloodstream infections in liver trans... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Transplantation proceedings Volume: 38 ISSN: 0041-1345 ISO Abbreviation: Transplant. Proc. Publication Date: 2006 Nov |
Date Detail:
|
Created Date: 2006-11-20 Completed Date: 2007-02-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0243532 Medline TA: Transplant Proc Country: United States |
Other Details:
|
Languages: eng Pagination: 2842-6 Citation Subset: IM |
Affiliation:
|
Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School at Houston, Houston, Texas 77030, USA. Barry.D.Kahan@uth.tmc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenal Cortex Hormones
/
therapeutic use* Adult Cyclosporine / pharmacokinetics, therapeutic use* Demography Drug Administration Schedule Drug Therapy, Combination Ethnic Groups Female Humans Immunosuppressive Agents / pharmacokinetics, therapeutic use Kidney Transplantation / immunology*, mortality Male Middle Aged Reoperation / statistics & numerical data Retrospective Studies Sirolimus / pharmacokinetics, therapeutic use* Survival Analysis Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Adrenal Cortex Hormones; 0/Immunosuppressive Agents; 53123-88-9/Sirolimus; 59865-13-3/Cyclosporine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Evaluation of performance factors affecting two formulations of cyclosporine in pediatric renal tran...
Next Document: MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients.